Benzydamine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Benzydamine: From Oral/Pharyngeal Anti-inflammatory to Benign Prostatic Hyperplasia
One-Sentence Summary
Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) with local anesthetic properties, commonly used for oral mucositis, pharyngitis, and gynaecological inflammation. The TxGNN model predicts it may be effective for Benign Prostatic Hyperplasia (BPH), with a high prediction score of 99.26%; however, no supporting clinical trials or published literature were identified, making this a model-only prediction at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Oral/pharyngeal inflammation (oral mucositis, pharyngitis); detailed regulatory indication data not available in India |
| Predicted New Indication | Benign Prostatic Hyperplasia (BPH) |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L5 — Model prediction only; no clinical trials or literature identified |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action (MOA) data for Benzydamine is not available in the current dataset. Based on established pharmacological knowledge, Benzydamine is a benzimidazole-derived NSAID with three theoretically relevant mechanisms that may connect it to BPH pathophysiology.
Anti-inflammatory axis: BPH pathogenesis is closely linked to chronic low-grade inflammation within the prostatic microenvironment, characterised by elevated levels of IL-6, IL-8, and TNF-α. Benzydamine is known to inhibit TNF-α translation and COX-dependent prostaglandin synthesis, which may theoretically attenuate the inflammatory proliferative stimulus in prostate tissue. This represents the strongest mechanistic rationale, though evidence remains indirect and organ-level data are absent.
Local anesthetic and sensory nerve modulation: Benzydamine’s sodium channel blocking activity may influence prostatic sensory afferent input, potentially improving subjective lower urinary tract symptoms (LUTS) perception without addressing the underlying tissue hyperplasia. Additionally, limited pharmacological data suggest a weak alpha-adrenoceptor antagonist activity, loosely analogous to tamsulosin; however, the potency is far below that of standard alpha-blockers and findings across literature are inconsistent. A critical limitation is that Benzydamine’s low systemic bioavailability from topical formulations may preclude therapeutically relevant prostatic tissue concentrations.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Benzydamine is currently not marketed in India. No drug approvals or product registrations were found in the regulatory dataset.
Safety Considerations
Please refer to the package insert for safety information.
(All available safety fields — key warnings, contraindications, and drug-drug interactions — contained no retrievable data in the current Evidence Pack. Full safety evaluation requires manual review of the CDSCO/manufacturer prescribing information.)
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model assigns a very high prediction score (99.26%), but all three evidence queries (ClinicalTrials.gov, ICTRP, PubMed) returned zero results for Benzydamine in BPH. With no human or preclinical in-vivo data, and critical gaps in both MOA characterisation and safety profiling, this candidate cannot advance past the hypothesis stage.
To proceed, the following is needed:
- Safety data remediation (Blocking): Obtain and parse the official prescribing information (package insert) to extract key warnings and contraindications before any S1 safety assessment can begin
- MOA confirmation: Retrieve structured mechanism of action data from DrugBank API (DB09084) to formally confirm TNF-α inhibition, COX inhibition, and sodium channel blocking as the operative pharmacology
- Preclinical evidence search: Conduct a broader literature search using MeSH terms (e.g., “benzydamine” AND “prostate” OR “LUTS” OR “alpha-adrenergic”) and expand to non-English databases; current query may have been too restrictive
- Prostatic pharmacokinetic data: Determine whether systemic absorption is sufficient to achieve therapeutic concentrations in prostate tissue — this is a critical feasibility gate given Benzydamine’s historically topical usage
- Exploratory in-vitro or in-vivo BPH model study: If mechanistic plausibility is confirmed, a preclinical proof-of-concept study would be the minimum threshold to elevate this candidate from L5 to L4
- India regulatory pathway: Since Benzydamine has no existing India registration, a full new drug application pathway would apply — factoring this into the development timeline is essential
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.